JW Pharma to participate in S.Korea’s new drug project

The company will receive two-year KDDF funding for non-clinical research of its hair loss treatment JW0061

JW Pharma to participate in S.Korea’s new drug project
Hyun-Ah Oh 1
2023-08-28 14:00:08 5hyun@hankyung.com
Bio & Pharma

South Korea's JW Pharmaceutical announced on Monday that its experimental hair loss drug, JW0061, has been selected for a two-year funding program by the Korea Drug Development Fund (KDDF), the country's premier public funder of pharmaceutical research and development.

JW0061, described as a groundbreaking drug candidate, aims to tackle hair loss by targeting the Wnt signaling pathway, a critical mechanism involved in skin and hair follicle development.

"The drug uniquely activates a new target, GFRA1, which is unrelated to male hormones," a company source said. "As a result, JW0061 is expected to be safe and effective for both male and female patients experiencing hair loss."

The funding boost from KDDF comes as JW Pharmaceutical is actively conducting toxicity assessments for the drug with the goal of launching clinical trials next year.

The company also revealed ongoing efforts to optimize a transdermal (patch-type) formulation, offering patients a more convenient treatment application.

The KDDF is a national consortium backed by three South Korean government ministries and is recognized as the largest public source of drug R&D funding in the country.

This funding initiative will cover non-clinical trial costs for JW0061 over the next two years.

Write to Hyun-Ah Oh at 5hyun@hankyung.com
##JW Pharmaceutical hair loss treatment JW0061 ##JW0061 funding program KDDF ##JW0061 Wnt CFRA1

JW Pharma gets OK for phase 3 clinical trials of URC102 in Taiwan

JW Pharma gets OK for phase 3 clinical trials of URC102 in Taiwan

The headquarters of JW Pharmaceutical in Gwacheon South Korea's JW Pharmaceutical has won approval from Taiwan's Food and Drug Administration (TFDA) to conduct phase 3 clinical trials for its gout treatment, Epaminurad (URC102), the company said on Friday.Epaminurad, an oral uric acid transport

JW Pharma unveils S.Korea's first homegrown hybrid incubator

JW Pharma unveils S.Korea's first homegrown hybrid incubator

South Korea's JW Pharmaceutical on Wednesday released three products from its new incubator brand Hi-Mammi.The company's rollout of hybrid and high- and low-end models was its first product launch since acquiring the medical device unit of affiliate JW Bioscience in January.The Hi-Mammi incuba

JW Pharma to use zebrafish in new drug development

JW Pharma to use zebrafish in new drug development

South Korean drug developer JW Pharmaceutical has entered into a memorandum of understanding (MOU) with Zefit, a domestic non-clinical trial institute that specializes in zebrafish models, to expedite the development of new drugs, the company said on Monday. As per the agreement, JW Pharmaceut

JW Pharma receives 1st overseas patent for its hair loss treatment

JW Pharma receives 1st overseas patent for its hair loss treatment

JW Pharmaceutical's headquarters JW Pharmaceutical, a drug company based in South Korea, has received its first patent for a hair loss treatment that is currently in development. This marks the first time that its candidate drug has been patented overseas. JW received on Monday a patent for JW0

JW Pharma to put AI into new drug ingredient development

JW Pharma to put AI into new drug ingredient development

South Korea's drug developer JW Pharmaceutical is expanding the scope of its artificial intelligence (AI) uses from new drug research to the development of active pharmaceutical ingredients (APIs).JW Pharmaceutical said on Monday that it has signed an agreement with Merck Life Science to resea
(* comment hide *}